ABBV · 10-Q · 2026Q2 · Full report

Operating Expense Trends

AbbVie Inc. · 2026-08-03 · Importance 34 · Surprise 58

SG&A expense increased 10.1% to $7.210 billion for the six months ended June 30, 2026 from $6.546 billion. SG&A as a percentage of revenue was flat because revenue growth leverage offset higher litigation reserve charges. R&D expense increased 14.7% to $4.816 billion from $4.198 billion as AbbVie funded all stages of its pipeline. Acquired IPR&D and milestone expense included a $650 million upfront charge for a RemeGen Co., Ltd. license agreement during the six months ended June 30, 2026.

Key facts

• Selling, general and administrative expense for the three months ended June 30, 2026: $3,632 million; for six months: $7,210 million; SG&A as a percentage of net revenues was flat compared to prior year and was favorably impacted by leverage from net revenues growth offset by higher litigation reserve charges. source
• Research and development expense for the three months ended June 30, 2026: $2,344 million; for six months: $4,816 million; R&D as a percentage of net revenues was flat compared to prior year and increased to support all stages of the pipeline. source
• Operating earnings for the six months ended June 30, 2026: $10.4 billion. source